PRESS RELEASE – New Jersey/New York, March 28, 2023 – Jonathan Levitt, a renowned trial attorney in the healthcare and life sciences industries and the co-founding partner of Frier Levitt, has been invited to testify before the U.S. Senate... Read More
Antitrust Tools Available to Combat PBM Abuse of Pharmacies | Articles | Biotech Companies | Chain Pharmacies | Community Oncology Practices & Other Dispensing Physician Practices | Community, Retail Pharmacies | Defending Pharmacies in PBM Audits | Digital Pharmacies | DIR Fees | Dispensing Physician Practices and Dispensing Physicians | Fertility Pharmacies | Home Infusion Providers | Integrated Delivery Network | Integrated Delivery Network and Hospital System Pharmacy | Long-Term Care Pharmacies | Manufacturers | National Board of Pharmacy Matters | News | Outsourcing Facilities (503B) | PBM Qui Tam Lawsuits | Pharmaceutical Manufacturers | Pharmaceutical Wholesalers | Pharmacy Transactions | Physician Dispensing | Plan Sponsor PBM Contract Services | Section 340B In-House and Contract Pharmacies | Specialty Pharmacies | State and National Pharmacy Associations | State Board of Pharmacy Hearings and Professional Discipline | Supermarket Pharmacies | Traditional Compounding Pharmacies (503A) | Urologist | Veterinary Compounders

As Pharmacy Benefit Managers (PBMs) review their retail pharmacy networks and conduct audits, pharmacies find themselves at risk for claim recoupment and audit discrepancies over dispensing ancillary drug products to patients when they did not fill... Read More
Antitrust Tools Available to Combat PBM Abuse of Pharmacies | Articles | Community, Retail Pharmacies | Life Sciences | Pharmacy Transactions

On December 31, 2021, Governor Hochul signed S. 3762/A. 1396 into law, one of the most comprehensive Pharmacy Benefit Manager (PBM) laws in the country. Frier Levitt previously reported on this bill as part of a suite of bills passed by the... Read More
Antitrust Tools Available to Combat PBM Abuse of Pharmacies | Chain Pharmacies | Community, Retail Pharmacies | Defending Pharmacies in PBM Audits | Life Sciences | MAC Pricing & Appeals | Pharmacy Law | Pharmacy Transactions | Plan Sponsor PBM Contract Services

Since CVS Caremark (“Caremark”) introduced the aberrant quantities list (the “List”) in 2019, Caremark has been adding more drug products to the List every year.  It now includes nearly 800 drug products and Caremark has been flagging... Read More
Articles | Community, Retail Pharmacies | Digital Pharmacies | Life Sciences | Pharmacy Law | Pharmacy Transactions | Specialty Pharmacies

The Section 340B federal discount drug program (340B program) is a federal program under which pharmaceutical manufacturers enter into contracts with the U.S. Department of Health & Human Services (HHS) in exchange for obtaining Medicaid and... Read More
340B Covered Entity and Contract Pharmacy Regulatory and Contract Support | Articles | Life Sciences | Pharmaceutical Manufacturers | Pharmacy Law | Pharmacy Transactions | Section 340B In-House and Contract Pharmacies

Direct and indirect remuneration (DIR) fees paid by pharmacy providers to pharmacy benefit managers (PBMs) are on the rise for the upcoming calendar year in 2022.  Pharmacy DIR fees have been utilized by PBMs to recoup monies on claims submissions... Read More
Articles | Chain Pharmacies | Community, Retail Pharmacies | Digital Pharmacies | DIR Fees | Life Sciences | Pharmacy Law | Pharmacy Transactions

Effective on January 1, 2022, the Centers for Medicare & Medicaid Services (CMS) and the Department of Health and Human Services (HHS) will implement the Final Rule for Medicare and Medicaid Programs. The Final Rule establishes pharmacy... Read More
Articles | Chain Pharmacies | Community, Retail Pharmacies | Defending Pharmacies in PBM Audits | Life Sciences | Pharmacy Law | Pharmacy Transactions | Plan Sponsor PBM Contract Services

Worldwide there are fewer than 500,000 people with hemophilia, a genetic disease that inhibits a patient’s blood clotting ability. Hemophilia is caused by genetic mutations in a patient and is hereditary, meaning that the condition is often passed... Read More
Articles | Community, Retail Pharmacies | Employment Matters | Life Sciences | National Board of Pharmacy Matters | Pharmacy Law | Pharmacy Transactions | Value Based Care | White Collar Criminal Defense & Government Investigations

On July 9, 2021, President Biden issued an executive order (EO) containing 72 directives to more than a dozen federal agencies, many of which have broad implications for healthcare. Specifically targeted are healthcare competition, hospital mergers,... Read More
Articles | Healthcare | Healthcare Law | Hospitals and Healthcare Systems | In-house Counsel Legal Support Services | Life Sciences | Pharmaceutical Manufacturers | Pharmacy Law | Pharmacy Transactions | Physician Dispensing | Physicians and Medical Practices of all Specialties | Professional Practice Representation | Regulatory Compliance, including FDA, DEA and HIPAA